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X-linked hypophosphatemic rickets (HYP) is the most common
form of familial hypophosphatemic rickets. Patients variably
prcsent with lower extremity deformities, rickets, short stature,
bone pain, dental abscesses, enthesopathy, and osteomalacia [1].
It is an X-linked dominant disorder [21 characterized by decreased
renal tubular phosphate reabsorption and consequent hypophos-
phatemia. Observations in the Hyp mouse, one of the murine
homologues of the human diseasc, indicate that the disorder is not
due to an intrinsic renal defect [3—6]. However, the HYP gene
may directly or indirectly regulate the expression of the sodium
dependent phosphate cotransporter (NPT2) in the renal proximal
tubule [7]. Despite extensive study, the pathophysiology of the
disorder has not been elucidated. To gain better understanding of
this disorder we have used the positional cloning approach to
locate and clone the HYP gene.
The positional cloning approach
The positional cloning approach has been used to identify genes
that are responsible for a variety of diseases [8]. The advantage of
this approach is that knowledge of gene function and tissue
expression are not necessary to locate the disease gene. Thus, one
does not need to make any assumptions about the gene. In these
studies investigators use linkage analysis to determine the chro-
mosomal location of the disease gene and to obtain genetic
markers that flank the gene. Subsequently, they attempt to obtain
"contig" maps, which are overlapping pieces of human DNA in
cosmid or yeast artificial chromosome vectors, that span the
region between the flanking markers. They locate the genes that
are contained within the contig and test them for mutation in
affected individuals [reviewed in 9—11]. The first step in positional
cloning is linkage analysis. Linkage analysis takes advantage of the
fact that reeombination is a fairly frequent event in meiosis. When
precursor cells undergo meiosis, homologous chromosomes re-
combine and exchange segments of equal length. This results in
the separation of loci on a chromosome, a process referred to as
crossing over. As a result, the germ cells contain chromosomes
that are a patchwork of segments from the two parental chromo-
somes. The closer two loci lie on the same chromosome the less
often they are separated during recombination. If two loci do not
freely recombine they are said to be linked. To quantify linkage
between two loci investigators use LOD scores. The LOD score is
equal to the log10 of the odds of linkage at a particular genetic
distance between two loci. A LOD (Z) score of  3 is evidence of
linkage (lOt)0:1) and a LOD score of -2 is evidence of non-
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linkage (100:1) [12]. LOD scores are calculated over a range of
recombination fractions (6), the genetic distance between two
linked markers. The best estimate for the reeombination fraction
(6) is that value at which the LOD score is maximized [Z(6)].
Additionally, investigators can determine whether a particular
genetic marker is centromerie or telomeric to a disease gene by
using multilocus analysis and/or analyzing individual reeombi-
nants.
Linkage studies in X-linked hypophosphatemic rickets
Initial studies by Machler et al [13] and Read et al [14] localized
the HYP gene to Xp22 using restriction fragment length polymor-
phisms (RFLP). Subsequently, Thakker et al [15] determined that
DXS41 and DXS43 are flanking markers for the HYP gene.
However, the flanking markers were much too far apart to enable
investigators to isolate and clone the HYP gene. To refine the
genetic map around the HYP locus we tested several RFLP
markers in the Xp22 region for linkage to HYP in 5 large kindreds
[16]. We determined that HYP is located between DXS2S7 on the
telomeric side and DXS41 on the centromeric side. The distance
between these two flanking markers is approximately 3.5cM.
Unfortunately, although the marker DXS365 was tightly linked to
HYP [Z(6) = 13.98 at 6 = 0.0],we were unable to locate DXS365
with respect to HYP since there were no reeombination events
between DX5365 and HYP. Indeed the RFLP for DX5365 was
not informative in the one mating that demonstrated a recombi-
nation event between DX5257 and HYP [16]. To be an informa-
tive mating the affected parent of the recombinant individual must
be heterozygous for the marker. Additional linkage data obtained
by Rowe et al[17] determined that DXS274 was linked to the
HYP gene [Z(0) = 4.2 at 6 = 0.0], but they were unable to locate
it with respect to HYP since there were no reeombination events
between the RFLP DXS274 and HYP. Since tightly linked
flanking markers are necessary prerequisites to obtain the HYP
gene by positional cloning techniques, we extended our linkage
studies to include an additional large HYP kindred to enable us to
determine the positions of DXS365 and DX5274 relative to the
HYP gene [18].
With the expanded family resources we found only one recom-
bination event between DX5365 and HYP [Z(6) = 17.43 at 6 =
0.012] and observed in this mating a recombination event between
HYP and the previously determined telomeric marker DX5257.
In contrast, in the same mating there was no recombination
between HYP and the more centromeric markers DX5274 and
DXS4I. In addition, we discovered two matings that demon-
strated reeombination events between HYP and DX5274
[Z(O) = 22.15 at 6 = 0.018]. Both of these matings placed
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DXS274 on the centromeric side of the HYP gene. These
observations established that DXS365 is telomeric to the HYP
gene, while DXS274 is centromeric to the HYP gene [18].
Simultaneously, Rowe et al [19] made a microsattelite repeat
marker for DXS274. Microsattelite repeat markers are multi-
allele markers [201 that are generally more polymorphic than
RFLPs. As a result they tend to have far fewer noninformative
matings. Combining their results for the microsattelite repeat for
DXS274 and the RFLP for DX5274, Rowe et al determined that
DXS274 lies centromeric to the HYP gene and telomeric to
DXS41 [19]. Thus the locus order supported by the above studies
was Xtel-DXS43-(DXS257/DXS365)-HYP-DXS274-DXS41-Xcen,
where a "1' between loci indicates that the order between them
could not be determined. To determine the relative location of
DXS257 and DXS365, we combined HYP kindreds from two
groups of investigators [18, 19] and analyzed recombination
events in these families with a newly available microsattelite
repeat for DXS365 [211. Our data demonstrated that DXS365 was
centromeric to DXS257 and was the closest telomeric marker to
HYP [22]. The new order was now Xtel-DXS43-DXS257-
DX5365-HYP-DXS274-DXS41-Xcen.
Physical mapping and the YAC contig map
The flanking markers, DXS365 on the telomeric side and
DXS274 on the centromeric side, were now close enough to try to
bridge the distance between them with yeast artificial chromo-
somes (YAC). YACs are yeast vectors that contain large pieces of
human DNA (up to 1 MB) and can be propagated in yeast [23].
DX5365 and DXS274, and/or cosmids that contained these
probes, were used to screen YAC libraries [24]. On the centro-
meric side DXS274 identified four nonchimeric YACs. Two of
these also contained the more centromeric marker DXS41. The
ends of YAC 83B05, which contains both DXS274 and DXS41,
were isolated and used to screen the four YACs that were
identified with DXS274. The trp end of YAC 83B05 hybridized to
YAC 80G04, which does not contain the probe DXS41. Thus, the
trp end of YAC 83B05 was the telomeric end and we used a
cosmid that contained this trp end to rescreen YAC library filters.
This cosmid identified several new YACs. On the telomeric side
of the HYP gene DXS365 identified two nonchimeric YACs.
Alu-PCR [25] was used to amplify sequences from one of these
YACs and these PCR products were used to rescreen the YAC
library. Five YACs were identified by this hybridization and three
of these had already been identified by the trp end of YAC 83B05.
Thus, as illustrated in Figure 1, we were able to span the HYP
region with three YACs and the physical distance between
flanking markers was approximately 1.5 Mb [24].
To further delineate the HYP region we derived new microsat-
ellite markers, DXS 1683 and DXS7474, from two of the YACs
[26, 27]. Both of these markers were physically mapped to lie
between the flanking markers DXS365 and DXS274 [24]. We
tested these markers in 20 large HYP kindreds. Two recombi-
nants were seen between DXS 1683 and HYP. Both of these
matings placed DXS 1683 on the centromeric side of the HYP
gene [22]. Similarly, there were two recombination events be-
tween DXS7474 and HYP which placed DXS7474 telomeric to
HYP [27]. The physical distance between these new flanking
markers is approximately 350 kb and they both are contained on
one YAC [27].
Since the distance between the new flanking markers is rela-
tively short and since cosmids have several advantages over YACs,
we constructed a cosmid contig [28] across the region (Fig. 1). The
cosmid contig allowed us to change our approach to mutation
detection. In addition to trying to isolate cDNAs from the HYP
region and test them for mutation in our 20 large kindreds, we
used the cosmids to screen large numbers of affected individuals
for deletions. These affected individuals were either members of
small kindreds that were not suitable for linkage studies or were
isolated cases. Through the collaborative efforts of the five
laboratories that make up the HYP consortium [28] we obtained
DNA samples from approximately 150 unrelated affected individ-
uals. We looked for deletions by hybridizing whole cosmids to
Southern blots of restriction enzyme digested genomic DNA from
these individuals.
Although deletions have never been found in HYP patients by
cytogenetic techniques, we thought that there might be small
deletions that would be detected by Southern blotting. Detection
of a deletion with a cosmid from the contig would be a strong
indication that the cosmid contained the HYP gene.
We found three affected individuals who demonstrated dele-
tions in DNA contained within cosmid 611. Two of these deletions
are approximately 6 and 17 kb in size. The third deletion is over
55 kb and extends on the telomeric side of cosmid 611 to include
cosmid 177. We found a forth affected individual who demon-
strated a small (approximately 1 kb) deletion within cosmid 1005,
which lies immediately centromeric to cosmid 611 [28]. This latter
deletion does not overlap with the other three deletions. Thus, we
focused our efforts on these cosmids.
Cloning the HYP gene
To clone the gene the members of the HYP consortium
employed two complementary approaches. We used the cosmids
that contained the deletions to screen eDNA libraries. Addition-
ally, we performed automated sequencing of the cosmids and
looked for exons within the genomic sequence. Both lines of
investigation revealed the presence of only one gene in the
approximately 100 kb region. Analysis of the available partial
sequence of this gene indicates that it contains significant homol-
ogy at the peptide level to a family of endopeptidase genes, which
includes neutral endopeptidase, endothelin-converting enzyme-i
and the Kell antigen. Further analysis revealed that in all four
patients who had deletions, the deletions involved at least one
exon from this gene [28]. We labeled this gene "PEX" for
phosphate regulating gene with homologies to endopeptidases on
the X chromosome.
Although computer searches of the genomic sequence failed to
identify any other gene in the region, it was possible (although
unlikely) that the PEX gene was not the HYP gene, but simply
another gene in the region that was also deleted in our four
affected individuals. To obtain more definitive evidence that the
PEX gene is the HYP gene, we looked for point mutations in our
patients. We determined the intron/exon boundaries for two PEX
exons and designed primers to amplify across the splice sites. PCR
products from our HYP families as well as controls were analyzed
by single stranded conformational polymorphism (SSCP). This
technique takes advantage of the fact that under nondenaturing
conditions single stranded DNA has a folded conformation that is
stabilized by intrastrand interactions. The conformation and
hence electrophoretic mobility of the molecule is dependent on its
sequence. Thus, single base pair changes alter the secondary
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Fig. 1. Schematic representation of YAC and cosmid contigs. Genetic markers are positioned at the top of the Figure from telomeric (DXS365) to
centromcric (DXS41). YACs 900EOl138, 900A0472 and 83B05 form the minimal YAC contig. YAC 900E01138 has a small deletion (not shown) in the
region of overlap with YAC 900A0472. A more detailed view of the HYP region is presented in the lower half of the figure, which contains the cosmid
contig. Adapted from references [24] and [281.
structure of the DNA and result in band shifting on nondenatur-
ing gels [29]. SSCP analysis of the two exons revealed aberrant
bands in three affected individuals. Sequencing these bands
demonstrated a frameshift mutation in one patient caused by loss
of a TC dinucleotide in the middle of one of the exons. Sequenc-
ing of the PCR product from the other two affected individuals
revealed two point mutations in the invariant dinucleotides of the
splice acceptor site of the other exon. Both of these latter
mutations would potentially lead to exon skipping and this was
confirmed in one of the patients by RT-PCR experiments [281.
These point mutations establish PEX as the HYP gene and we are
currently defining additional mutations.
Tissue expression
Although RT-PCR has been successfully performed using
lymphocyte and fetal brain RNA, it is not likely that these are the
most physiologically relevant sites of tissue expression. PEX gene
cDNAs have been used to scrccn Northern blots from multiple
human and mouse tissues. So far, no signals have been detected.
It is possible that, in the normophosphatemic individual, the PEX
gene is expressed at levels that are insufficient to allow detection
by Northern blotting. Alternatively, we may not have tested the
appropriate tissue yet. More detailed studies of tissue expression
are currently underway.
Mechanism
Any model that proposes to explain the role of the PEX gene in
normal phosphate homeostasis and how mutations in the PEX
gene cause the HYP phenotype must take into account several
observations. First, HYP is an X-linked dominant disorder [2].
HYP could be a haploinsufficiency disorder where having half the
normal complement of the normal PEX gene could lead to
disease. Alternatively, mutation of the PEX gene could result in a
dominant negative effect. Second, the two known sodium depen-
dent phosphate cotransporters are on chromosome 5q35 [30] and
t5p [311. Data presented on the Hyp [7] and Gy [32] mice, murine
homologues of the human disease, indicate that there is approx-
imately a 50% reduction in NPT2 mRNA in mutant mice,
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N
9O0OJ59 (6601W) I
cosmid H10174 DXS274 DXS41
cb) I
r,i 83005 (660kb)
173A01 (370kb) IN
I 27C06 (400kbNI
I 80004 (440kb)
I 135011 (460kb)
'(AC 900A0472
rrrsssrssssrsrssssssrsssa
DXS7474
HYP
cosl 77
cos6ll
DXS1 683
cos0262 Co 635
cos65B'
1036 Econs: Positional cloning of the HYP gene
indicating that murine Hyp/Gy gene has a role in the regulation of
NPT2 expression. Third, when osteoblasts from Hyp mice are
transplanted into the normal mouse there is a persistent miner-
alization defect despite the normal hormonal and biochemical
environment [33, 341. Thus, either the HYP gene is expressed in
the osteoblast or the abnormal environment in the Hyp mouse has
prolonged effects on the osteoblast. Fourth, studies done by
Nesbitt and colleagues [5] demonstrate that when kidneys from
Hyp mice are transplanted into nephrectomized normal mice the
kidneys conserve phosphorous normally. When kidneys from
normal mice are transplanted into nephrectomized Hyp mice the
kidneys waste phosphorus. Thus, the disease is neither transferred
nor corrected by renal cross-transplantation and the kidney is not
the major organ of PEX expression. Fifth, when Hyp and normal
mice are joined together in parabiosis experiments the normal
mouse becomes hypophosphatemic. Parabiosis does not correct
the Hyp phenotype. This implies that the Hyp phenotype is caused
by the elaboration of a humoral factor that is produced in
excessive amounts [3, 4]. Indeed, there are tumors that produce
isolated renal phosphate wasting, which resolves with resection of
the tumor. Unfortunately, this factor(s), which we have referred to
as phosphatonin has only been partially purified [35, 361.
There are several possible mechanisms of action of the normal
PEX gene product. Since the deletions and frameshift mutations
that we observed in the PEX gene in DNA from several affected
individuals are likely to cause loss of function of the PEX gene
product, it is extremely unlikely that these mutations are activat-
ing mutations. Thus, PEX is not the phosphatonin gene. It is more
likely that the PEX gene has other roles in phosphate homeosta-
sis. The PEX protein could normally function to degrade phos-
phatonin. Thus, mutations in the PEX gene would result in
inability to degrade phosphatonin and lead to renal phosphate
wasting. However, if this were the case, parabiosis of Hyp and
normal mice would have led to rescue of the Hyp phenotype
rather than renal phosphate wasting in the normal mouse, since
one would expect that the normal mouse would be able to degrade
the excess phosphatonin. This assumes that the PEX protein
would come into contact with phosphatonin before phosphatonin
could cause renal phosphate wasting. Another possibility is that
the PEX protein normally functions to activate a phosphate
conserving hormone. This possibility becomes more plausible
when one considers data presented at this meeting that human
Stanniocalcin stimulates phosphate reabsorption when adminis-
tered to rats [371. However, this model would also predict rescue
of the Hyp phenotype in the parabiosis experiments. A fourth
possibility that fits in with the currently available data are that the
PEX gene functions to inhibit the expression of phosphatonin
indirectly. Thus, mutations of the PEX gene would indirectly
result in over expression of phosphatonin and lead to renal
phosphate wasting.
While it is clear that much work needs to be done, the cloning
of the PEX/HYP gene will provide us with new insights into
X-linked hypophosphatemic rickets and normal phosphate ho-
meostasis. Data presented at this conference indicate that the
control of serum phosphate is a fascinating, but complex process.
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